Chronic Obstructive Pulmonary Disease Report Will Give You a Physician's Insight into This Exciting Subject.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c91368)has announced the addition of new Decision Resources report "Target Product Profiles 2008: Physician Insights on Key Attributes - Chronic Obstructive Pulmonary Disease" to their offering.

A novel, nonsteroidal, anti-inflammatory therapy that increases the forced expiratory volume in one second (FEV1) over placebo equal to or greater than fluticasone (GlaxoSmithKline's Flovent) for the treatment of COPD.

Using Target Product Profiles in Your Market Strategy

Our Target Product Profiles qualitatively predict the market potential of a drug fulfilling a key unmet need. This information is critical for evaluating the impact of clinical attributes on physician prescribing of emerging agents, whether the emerging drug is your own or a competitor's. Examples of how to use the information you will find in this report are highlighted below:

- For companies who are developing a drug with some of the characteristics we are testing, our survey results reveal the standards that surveyed physicians expect the remainder of the drug's clinical profile to meet. Our analysis begins to uncover physician-expected drug attributes as well as acceptable trade-offs in emerging therapies. Our primary research with practicing physicians includes this emerging therapy's anticipated patient share, projected use by line of therapy, and forecasted sales.

- For companies that already have a drug launched for the indication in question, our data and analysis show the impact an emerging drug would have on their brand's market. Not only does our research reveal which existing brands would be replaced by a drug meeting the Target Product Profile, but it also clearly outlines whether any drugs in the pipeline will meet the criteria laid out by physicians to challenge the existing sales leader. This knowledge gives existing brands the information they need to protect their share, either through new clinical trials aimed at end points physicians say are critical differentiators or by aggressive marketing of brand attributes that emerging agents will not be able to beat.

- For companies looking to enter a disease through licensing or acquisition, the challenge of sifting through tens or hundreds of early-stage candidates can be daunting. Our Target Product Profiles can quickly show business development teams the clinical attributes that are unique versus products already on the market, and our primary research with physicians quickly identifies likely share and market potential to give a first glimpse at valuation.

Because all of our Target Product Profiles are designed to be attainable within the next decade, our research can be a fast and efficient way to whittle the field of potential licensing candidates down to the most valuable few.

Contents:

Introduction

Using Target Product Profiles in Your Market Strategy

Report Contents

Target Product Profile Methodology

Etiology and Pathophysiology 

Overview

Anatomy

Disease Definition

Current Guidelines

Spirometric Measurement and Disease Severity

Causes of Airflow Limitation

Differentiating COPD and Asthma

Etiology Exposure to Noxious Particles

Impaired Lung Development

Genetic Factors

Other Risk Factors

Pathophysiology

Role of Inflammatory Cells

Receptors and Proteins Implicated in Inflammation

Protease-Antiprotease Imbalance

Oxidative Stress 

Direct Airway Damage

COPD Progression

Target Product Profile Discussion--Chronic Obstructive Pulmonary Disease

Target Product Profile Summary for Chronic Obstructive Pulmonary Disease--2011

Assessing Drug Development Opportunities

Physician Survey Results

Efficacy

Safety and Tolerability

Delivery

Estimated Patient Share

Pricing Potential

Forecasted 2016 Pricing Environment

Competitors to Watch

Emerging Product Profile

For more information visit http://www.researchandmarkets.com/reports/c91368